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Deferroxamine Preconditioning Promotes Long-Lasting
Retinal Ischemic Tolerance
Yanli Zhu,1 Lihong Zhang,1 and Jeffrey M. Gidday1,2

Abstract

Objective: “Ischemic tolerance” can be induced in the retina by “preconditioning” with brief periods of noninjurious retinal ischemia or systemic hypoxia. The present study was undertaken to assess whether tolerance
can be induced pharmacologically by deferroxamine (DFX), an iron chelator, which promotes the expression
of the transcription factor, hypoxia-inducible factor 1-alpha (HIF-1), and to identify potential HIF-1-induced
effectors of this endogenous protective response.
Methods: ND4 Swiss-Webster mice were preconditioned with DFX (200 mg/kg, intraperitoneally) as a single
dose (SDP) or as repetitive doses (RDP; 6 doses over 2 weeks) and then subjected to 30 min of retinal ischemia
(by intraocular pressure elevation) 1 or 4 weeks later. Retinal layer thicknesses and cell counts were quantified
1 week after ischemia. Retinae of additional mice were obtained at various times after SDP or RDP to examine
protein-level expression of HIF-1 and adrenomedullin (ADM), a HIF-1 gene target, by immunoblotting and
immunohistochemistry.
Results: Ischemia-induced injury was significantly attenuated by SDP 1 week earlier, but not when SDP occurred 4 weeks earlier. However, RDP performed 4 weeks earlier was potently neuroprotective. DFX robustly
induced HIF-1 protein expression throughout the inner retina, and levels of HIF-1 protein remained significantly elevated over the 1- and 4-week periods of time between the respective SDP and RDP stimulus and the
induction of retinal ischemia. Increases in ADM protein expression were evident throughout the retina following both preconditioning treatments.
Conclusions: DFX preconditions the retina against ischemic injury and multiple doses promote a long-lasting,
ischemia-protective phenotype. The widespread and protracted elevations in HIF-1 protein levels and the robust expression of one of its neuroprotective, prosurvival gene targets, ADM, strongly suggest that DFX-induced preconditioning is HIF-1-dependent. The ability to pharmacologically induce ischemic tolerance in the
retina by a clinically well-tolerated drug underscores the potential therapeutic utility of preconditioning for
retinal protection in various ischemic retinopathies.

Introduction

N

ONINJURIOUS BRIEF ischemia or systemic hypoxia are effective preconditioning stimuli known to promote a
state of increased ischemic resistance, or “ischemic tolerance,” in the retina.1,2 The endogenous basis for this protection is thought to result from the preconditioning-induced
transcriptional activation of a host of survival-promoting
genes, as well as post-translational protein processing, that
affect metabolic, inflammatory, excitotoxic, apoptotic, and
oxidative injury pathways.3 In brain models of ischemic tolerance, cytokines, metabolic inhibitors, anesthetics, and a
number of pharmacologic treatments can serve as preconditioning stimuli. However, relatively little is known about

pharmacologic approaches to establishing ischemic tolerance
in the retina. Ultimately, the clinical applicability of preconditioning to ischemic disease will require pharmacologic
therapies that activate endogenous, prosurvival pathways in
that tissue.
The present study was undertaken to assess whether deferroxamine (DFX), when administered as a preconditioning
stimulus, would afford retinal protection in the setting of
ischemia. The efficacy of DFX as a preconditioning agent was
shown previously in cerebral ischemia models,4,5 but its utility for retinal preconditioning has yet to be explored. We also
aimed to test the hypothesis that the duration of the period
of ischemic tolerance so induced could be extended, as we
showed previously for hypoxic preconditioning,6 by repeti-
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tive DFX treatments. We also sought to explore the mechanistic basis for this protection by focusing on the spatiotemporal expression of the transcription factor, hypoxia-inducible factor 1-alpha (HIF-1) and one of its gene products,
adrenomedullin (ADM). Our examinations of the involvement of this particular transcription factor and one of its cytoprotective, prosurvival gene targets was predicated based
on the fact that DFX, like cobalt choride,7 can act as a hypoxia-mimetic and stabilize HIF-1 expression,8,9 thereby
driving the expression of hypoxia- or stress-sensitive genes
that, we hypothesize, contribute to the ischemia-tolerant
phenotype.
Methods
All experiments were performed in accordance with the
Association for Research and Vision in Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmology and Vision Research and were approved by the Animal
Studies Committee at Washington University School of Medicine (St. Louis, MO). All studies were conducted on 10–12
week-old adult male Swiss-Webster ND4 mice (25–34 g; Harlan Sprague Dawley, Indianapolis, IN).
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1 drop of 0.5% proparacaine hydrochloride (Bausch & Lomb
Pharmaceuticals, Inc., Tampa, FL), a contact lens was placed
with saline to protect the cornea from dehydration. A 32-G
needle attached to a saline-filled reservoir (0.9% sodium
chloride; Baxter, Deerfield, IL) raised above the animal was
introduced into the anterior chamber to increase intraocular
pressure (IOP) above systolic blood pressure (IOP raised to
90 mmHg) and was used to induce retinal ischemia for 30
min, and a whitening of the anterior segment of the eye and
blanching of the retinal arteries, as observed under a surgical
microscope, were used as indices of complete retinal ischemia.
At the end of the ischemic period, the needle was removed
from the anterior chamber, and 1% atropine and 1%
Vetropolycin HC ointment (Fougera & Atlanta, Inc., Melville,
NY) was applied to the conjunctival sac. The animals were recovered in their home cages for 7 days prior to histologic
analyses of injury. The fellow eye of each animal served as a
nonischemic control, and results from these controls were
pooled with additional data from eyes obtained from anesthetized, but untreated, nonischemic mice. Animals were randomized into nonischemic and ischemic treatment groups,
and untreated and DFX-preconditioned treatment groups.
Histology and injury quantification

Single and repetitive DFX preconditioning
Two DFX-based preconditioning protocols were studied
for their ability to provide short- and long-term protection
of the retina against ischemic injury and for the changes in
retinal protein expression these treatments elicited. Mice
were randomized to receive either a single DFX preconditioning (SDP), in which one 200 mg/kg intraperitoneal (i.p.)
injection of DFX was administered, or repetitive DFX preconditioning (RDP), in which DFX was administered (200
mg/kg, i.p.) 6 separate times over a 2-week period, every
other day. Some animals from each of these two groups were
sacrificed at various times after SDP or the last RDP stimulus for immunohistochemical or immunoblotting analyses of
DFX-induced changes in retinal protein expression. Some animals in the SDP group were subjected to retinal ischemia 1
or 4 weeks later, whereas a 4-week waiting period was followed prior to ischemia in the RDP group. Respective
matched sham groups of SDP- and RDP-treated mice not
subjected to ischemia were also studied for each of the endpoints examined, as well as nonischemic controls not treated
with DFX, but maintained under similar conditions over
identical 1- and 4-week time periods.
Induction of retinal ischemia
Retinal ischemia was performed, as described previously,
wherein we provided extensive morphologic and functional
endpoints documenting the dependence of retinal injury on
ischemic duration in this same strain of mice.2,6 In brief, animals were anesthetized i.p. with chloral hydrate (350
mg/kg; Sigma Chemical Co., St. Louis, MO) and xylazine (4
mg/kg; Burns Veterinary Supply, Inc., Rockville Center,
NY), and core body temperature was maintained at 37°C
throughout the procedure with a thermoregulated infrared
heating lamp, while protecting the surgical eye from this
source. Pupils were dilated with 1% tropicamide/2.5%
phenylephrine hydrochloride (NutraMax Products, Inc.,
Gloucester, MA), and after achieving corneal analgesia with

Thicknesses and cell counts in the different retinal layers
were quantified, as described previously.6 In brief, following transcardiac perfusion (5 mL/min) with 50 mL of 10 mM
of phosphate-buffered saline (PBS; Sigma ImmunoChemicals, St. Louis, MO) and 100 mL of 4% paraformaldehyde
(Electron Microscopy Sciences, Fort Washington, PA), eyes
were enucleated and immersion fixed for 1 h in 4% paraformaldehyde, then transferred to 10% neutral-buffered formalin (Fisher Scientific, Pittsburgh, PA) overnight. Following
paraffin embedding, 5-m-thick serial sections, including the
optic nerve, were obtained from appropriately matched samples, using a rotary microtome (Reichert-Jung; Model 2030
Reichert-Jung, Vienna, Austria), dried overnight at 37°C, and
stained with hematoxylin and eosin.
Image-analysis software (Image-Pro Plus; Media Cybernetics, Silver Springs, MD) was used to measure the thickness of the different retinal layers, in triplicate, for both superior and inferior quadrants at a fixed distance (750–1000
m) from the edge of the optic disc; a minimum of three sections were used for each eye. Distances from the outer limiting membrane (OLM) to the inner limiting membrane
(ILM) (OLM-ILM) and the thickness of the inner nuclear
layer (INL) and the inner plexiform layer (IPL) were quantified. We also counted the total number of morphologically
identified living cells in the INL and ganglion cell layer
(GCL) in the same topographic region of the retina over
lengths of 75 and 250 m, respectively, to avoid possible regional anatomic variations. All morphometric measures
were performed in a masked fashion with regard to prior
sham or experimental procedures.
Immunoblotting
Four (4) h, 24 h, 1 week, and 4 weeks after SDP, and 4 h,
24 h, 1 week, 4 weeks, and 8 weeks after RDP, mice were
killed by cervical dislocation, and mouse retinae were isolated and frozen as rapidly as possible; whole-cell lysates
were prepared from retinae pooled from 2 retinas from 1
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mouse for the control and DFX-treated, nonischemic mice.
Age- and sex-matched retinae from control mice that did not
receive DFX were processed in parallel. Antibodies used included a polyclonal rabbit antimouse HIF-1 antibody
(1:500; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or
monoclonal mouse antimouse -actin antibody (1:20,000;
Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidase (HRP)-linked antibodies (Cell Signaling Technology,
Bevery, MA) to goat antirabbit IgG (1:3000) or horse antimouse IgG (1:3000). Protein in the resultant bands was quantified with Image J software [National Institutes of Health
(NIH), Bethesda, MD] and were normalized to protein levels in naïve controls.
Immunohistochemistry
The cellular localization of HIF-1 and ADM expression at
various times following SDP and RDP was determined by immunohistochemistry of paraffin-embedded sections of mouse
retina close to the central retina. As described earlier,6 following deparaffinization and rehydration, and antigen retrieval by
unmasking solution (Vector Laboratories, Burlingame, CA),
nonspecific binding was blocked with prediluted normal goat
serum (Vecastain Elite ABC kit; Vector Laboratories), and sections were incubated overnight at 4°C with primary antibody
[a chicken antimouse HIF-1 antibody (1:50) kindly supplied
by Dr. Max Gassmann, Ph.D., Zurich, Switzerland] and a rabbit, antimouse ADM antibody (1:100; Phoenix Pharmaceutics,
Inc., Burlingame, CA). For HIF-1, the secondary antibody was
a rabbit antichicken IgY HRP (1:500; Promega, Madison, WI),
with a diaminobenzidine-peroxidase conjugate (Vector Laboratories), and hematoxylin counterstaining. For ADM, a goat,
antirabbit IgG (1:200; AlexaFluor 568, Invitrogen-Molecular
Probes, Inc., Carlsbad, CA) was used as the secondary antibody. Negative control slides were run without primary antibody. Slide sections were examined and photographed by light
and fluorescent microscopy and analyzed with Axiovision software (Carl Zeiss, Gottingen, Germany).
Statistical analyses
Differences in the morphologic endpoints and protein expression by immunoblotting were compared by the nonparametric Kruskas-Wallis analysis of variance rank-sum
test. A value of P  0.05 was accepted as significant.
Results
Ischemic injury and DFX-mediated protection
Histologic analyses shown in Figure 1 reveal that both SDP
and RDP regimens we used were profoundly neuroprotective in the ischemic retina. Relative to controls (n  15), in
eyes without any prior DFX preconditioning treatment (n 
9), 30 min of retinal ischemia reduced OLM-ILM thickness
by 24% and the thickness of the INL and IPL by 16 and 36%,
respectively (all P  0.02). Loss of cells in the INL and GCL
was 21 and 32%, respectively (both P  0.001).
When SDP was performed 1 week before retinal ischemia
(n  5), all morphologic indices of retinal ischemic injury
were significantly reduced. Relative to ischemia, the extent
of protection realized by SDP was a 73–131% recovery for
the different retinal thicknesses (P  0.02) and a 87–95% recovery for cell counts (P  0.05). In all instances, except IPL
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thickness, these metrics were not significantly different in
magnitude from those measured in respective nonischemic
control mice. The ability of SDP to protect the retina against
ischemic injury was lost if the time between the SDP stimulus and the ischemic event was extended to 4 weeks. In these
9 mice (data not shown), trends toward recoveries in retinal
layer thicknesses (INL and IPL) were observed, but only the
overall thickness metric (OLM-ILM) was significantly improved (by 53%, relative to the 82% recovery in OLM-ILM
thickness measured when ischemia was induced 1 week after SDP). No significant protection was observed with respect to INL and GCL cell counts at this time.
However, when RDP was used as the preconditioning
stimulus, retinal neuroprotection was evidenced 4 weeks
later. A 87–127% recovery of ischemia-induced retinal thinning was measured in these mice (P  0.004), along with a
68–70% recovery in INL and GCL cell counts (P  0.05),
when ischemia was induced 4 weeks after the last of the six
RDP stimuli (n  7). These measures did not differ significantly from those in nonischemic controls.
Examination of nonischemic fellow eyes revealed that neither the SDP or RDP regimens significantly affected any of
the five morphometric endpoints relative to nonischemic
controls (Fig. 1).
HIF-1 expression following DFX preconditioning
Figure 2 provides immunohistochemical evidence for the
widespread induction of HIF-1 throughout the retina in response to a single systemic injection of DFX. During baseline,
normoxic, untreated conditions, some HIF-1 protein appeared to be expressed very faintly in some ganglion cell bodies and axons, in scattered cells in the inner nuclear layer, and
in the inner segments of the photoreceptors (Fig. 2B). In response to DFX, HIF-1 protein levels were rapidly (within 1
h) upregulated in the GCL, INL, and ONL layers, the photoreceptor inner segments, and the retinal pigment epithelial
cells, with a less robust expression in the nerve fiber layer and
outer plexiform layer, (OPL), and no staining in the IPL (Fig.
2C). In the GCL and INL, both the cytoplasm and nucleus are
positive for HIF-1, whereas in the ONL, it is the cytoplasm
that appears positive, surrounding unstained nuclei.
Figure 3 summarizes the changes in HIF-1 protein expression we observed following SDP and RDP, as determined by Western blotting. Note that SDP resulted in a
robust, significant increase in retinal HIF-1 protein expression within 4 h, which remained elevated for 24 h. In
fact, HIF-1 protein levels were still significantly elevated
above baseline 1 week after the single DFX injection, at a
time when the retina was still protected from retinal ischemic injury; however, 4 weeks following SDP, when ischemic tolerance was no longer evident, HIF-1 levels had
returned to baseline. From 4 h to 1 week following the last
of the 6 DFX injections that comprise the RDP stimulus,
retinal HIF-1 expression was also significantly elevated
to a similar magnitude as that induced by a single DFX
injection. Moreover, retinal HIF-1 levels were still significantly increased above baseline 4 weeks after RDP, a
time when the retina was still ischemia tolerant. However,
8 weeks after RDP, HIF-1 levels had returned to baseline, and the retina was no longer protected by an RDP
stimulus administered 8 weeks earlier.
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FIG. 1. Histologic analyses of retinal ischemic injury and protection by single deferroxamine (DFX) preconditioning (SDP,
hatched bars) and repetitive DFX preconditioning (RDP, cross-hatched bars). Retinal layer thicknesses are shown in the top
row (A–C), and retinal cell counts in the inner nuclear layer (INL) and ganglion cell layer (GCL) are shown in the bottom
row (D and E, respectively), as measured in retinal thin sections obtained 1 week after ischemia or at matched time points
in nonischemic mice. Note that the significant thinning of all retinal layers and the cell loss in the INL and GCL in response
to 30-min ischemia in untreated animals (NT, solid black bars; n  9) was nearly completely abrogated by prior preconditioning with SDP 1 week earlier (n  5) or RDP four weeks earlier (n  7). Layer thicknesses and cell counts in the nonischemic fellow eyes of ischemic mice with SDP and RDP are also shown (with no significant changes). *P  0.05 versus controls (C, gray bars; n  15); #P  0.05 versus untreated ischemia.

ADM expression following DFX preconditioning
The widespread retinal distribution of ADM protein expression at various times after SDP and RDP is shown by
the immunohistochemistry results in Figure 4. In general,
these stimuli led to a widespread expression of ADM
throughout the retina, and in both instances, this expression
was long lasting. Under baseline conditions (normoxia) without DFX, expression of ADM protein was noted at mild levels in the cytoplasm of scattered cells in parts of the GCL,
INL, ONL, and retinal pigment epithelium (Fig. 4A). At 4 h
after a single dose of DFX (Fig. 4B), ADM expression was elevated in all retinal regions that expressed it basally. By 24
h after DFX, ADM expression was similar in the GCL and
somewhat diminished in the INL and ONL relative to 4 h;
by 24 h, ADM expression was then noted in the IPL and more
robustly in the photoreceptor outer segments (Fig. 4C). One
(1) week after SDP, an elevated ADM expression was still
evident in the GCL, as well as in the INL, ONL, and IPL, and
in the retinal pigment epithelium, at levels similar to those
observed at 4 and 24 h; but the expression in the photore-

ceptor outer segments was attenuated relative to 24 h (Fig.
4D). Four (4) weeks following the last of the RDP treatments,
ADM expression was still robustly elevated in the GCL, INL,
and ONL, as well as in the IPL, photoreceptor outer segments, and RPE, at levels similar to that observed at 1 week
following SDP (Fig. 4E).
Discussion
Results of the present study are the first to document DFX
preconditioning as a therapeutic approach for establishing
retinal ischemic tolerance. A single dose of this agent robustly protected the retina from ischemic damage for at least
1 week, but protection was no longer evident 4 weeks later.
However, multiple doses of DFX over a 2-week period provided equally robust ischemic protection lasting at least 1
month after the last DFX treatment. The temporal profile
over which these two ischemia-tolerant states were established by DFX paralleled that of retinal HIF-1 protein expression, suggesting that the continued expression of one or
more of its downstream targets contributed to the neuro-
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FIG. 2. Representative immunohistochemistry for retinal hypoxia-inducible factor 1-alpha (HIF-1) protein expression in
control mice and 1 hour after a single preconditioning dose of deferroxamine (SDP). (A) Negative control without primary
antibody. (B) Normal control with primary antibody, showing only faint and scattered expression of HIF-1. (C) At 1 h after SDP, with widespread expression of HIF-1 evident throughout the retina. Scale bar  50 m.

protective phenotype. Indeed, we documented an elevation
of ADM protein expression throughout the retina following
both of our DFX preconditioning regimens, occurring along
a time course similar to that of HIF-1. These findings identify DFX, already approved for human use, as a potential
pharmacologic trigger for preconditioning the retina of patients at risk for various ischemic retinopathies.
In the central nervous system (CNS), and all other tissues
examined, a transient period of increased resistance to ischemic injury, known as “ischemic tolerance,” can be induced
by an assortment of “preconditioning” stimuli.3,10 The ability of brief ischemia1,2,11,12 to precondition the rat retina
against ischemic injury is now well established; systemic hypoxia is also effective,2,6 at least in mice. However, these
stimuli are not ideal options for promoting ischemic toler-

ance in humans. Relative to investigations using brief
ischemia or hypoxia, studies documenting pharmacologic
preconditioning of the retina are relatively sparse. Mitochondrial KATP channel openers13,14 effectively precondition
rat retina. Cobalt chloride, which activates the transcription
factor, HIF-1,15 increases the level of retinal vascular glucose transporters16 and upregulates heat-shock protein-27,7
which promotes retinal ischemic tolerance in rats.7 Our present study, identifying two different DFX preconditioning
protocols that promote short- and long-lasting ischemic tolerance in mouse retina, provides the first documentation of
DFX-mediated preconditioning in the eye.
DFX was originally identified decades ago for iron-chelation therapy in patients with transfusion-dependent anemias
(see below), but is increasingly becoming recognized for its

FIG. 3. Immunoblot analyses of retinal hypoxia-inducible factor 1-alpha (HIF-1) protein expression at various times (4
or 24 h and 1, 4, or 8 weeks) after single deferroxamine (DFX) preconditioning (SDP, hatched bars) or repetitive DFX preconditioning (RDP, cross-hatched bars), relative to controls (C, gray bar). Responses were normalized to HIF-1 protein levels in nonpreconditioned controls collected concurrently and run simultaneously. *P  0.05 versus control. n  6–9 mice for
experimental samples, n  11 for controls.
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FIG. 4. Fluorescent immunohistochemistry for adrenomedullin (ADM) expression in representative retinae of mice at various times following single deferroxamine (DFX) preconditioning (SDP) or repetitive DFX preconditioning (RDP). (A) Nonpreconditioned control. (B–D) At 4 h, 24 h, and 1 week after SDP. (E) At 4 weeks after RDP. ADM immunoreactivity shown
in red against a blue DAPI nuclear counterstain. Scale bar  50 m.

“hypoxia-mimetic” qualities as a result of its ability to stabilize the hypoxia-driven transcription factor, HIF-1, under
normoxic conditions. This results from its ability to disrupt
the association between the iron-dependent prolyl hydroxylase enzyme and HIF-1, so that ongoing ubiquitation-mediated degradation of the latter is prevented8,9; HIF-1 then
translocates to the nucleus and drives the expression of hypoxia-sensitive genes, whose protein products promote an
assortment of prosurvival actions.9,17 Although the DFX-mediated chelation of iron may also attenuate Fenton reaction
chemistry, thereby reducing superoxide radical generation,18
it is difficult to postulate how an attenuation in reactive oxygen species (ROS) would drive gene expression related to
preconditioning, particularly since ROS promote HIF-1 expression19 and participate in triggering ischemic tolerance.20
It is also unclear how, if DFX has a significant effect with respect to interrupting the cell cycle,21 such a response would
contribute to DFX-mediated preconditioning. Rather, given
the widespread evidence for a role for HIF-1 as a proximal
mediator of preconditioning in the retina6,7,22 and brain,4,23,24
we contend that it is the ability of DFX to stabilize HIF-1
in a dose-dependent, temporally unique manner that is responsible for its protective effects in our mouse model of retinal ischemia.
Indeed, our immunoblot measures of HIF-1 in the present study confirm that systemically administered DFX promotes significant, and relatively long-lasting, increases in the
expression of this transcription factor in the retina, similar
to that shown elsewhere in the CNS4,5 and other tissues25 at
comparable doses. Moreover, in those in vivo studies, as well
as in ours, it was conclusively demonstrated that DFX preconditioning promoted ischemic tolerance. A similarly protracted HIF-1 response was documented previously in the
rat brain in response to global ischemia, wherein the expression of HIF-1 protein was elevated for at least 1 week.26
In the retina, we measured a prolonged period of HIF-1 expression following hypoxic preconditioning, the magnitude
and duration of which was related to whether the hypoxic
stimulus was presented singly or repetitively.6 The present
results with DFX largely parallel these latter findings, but
with potentially important differences. The duration of the
resultant HIF-1 upregulation was greater with both SDP
and RDP relative to single and repetitive hypoxic preconditioning; with RDP, but not SDP, this increase in HIF-1 expression lasted at least 4 weeks. And, although the extent to

which HIF-1 expression was elevated in the retina was similar with SDP and RDP, and was of relatively moderate magnitude, a significantly greater increase in HIF-1 expression
followed repetitive, relative to single, hypoxic preconditioning.6 While considerable evidence supports a rapid “on response” for HIF-1 expression that, in most tissues, is proportionally dependent on the extent of oxygen-tension
reduction,9,17,27 our present results with DFX are similar to
our previous study with hypoxia, in that the “off response”
does not appear to be controlled in the same way, with HIF1 expression continuing well into normoxic recovery in a
fashion dependent on the characteristics of the preceding hypoxic stimulus.28,29 Recent studies of HIF-1 regulation following intermittent hypoxia also point to responses that are
uniquely related to the nature of the triggering stimulus.30
These magnitude- and duration-dependent differences in
HIF-1 expression may be just one more reflection of the
many different ways in which this transcription factor is
translationally regulated by hypoxia, DFX, and other stimuli.31,32
Our immunohistochemical studies to localize HIF-1 following DFX preconditioning also revealed interesting, stimulus-dependent differences in expression patterns relative to
hypoxic preconditioning. In the present study, DFX treatment led to HIF-1 expression in the cells of the GCL, INL,
and photoreceptor inner segments, whereas a more widespread induction of HIF-1, including ONL cells and some
plexiform layer expression, resulted following hypoxic preconditioning.6 However, only limited time points were studied in both studies, so we cannot rule out that expression
patterns may have been similar at other times, or that intraretinal pharmacokinetics influenced the response to DFX.
In any event, the increases in retinal HIF-1 protein expression following DFX preconditioning, that we documented,
implicate the downstream gene targets of HIF-1 as likely
effectors of the ischemia-tolerant state so induced.
The administration or pharmacologic upregulation of several HIF-1 gene targets, including erythropoeitin,33 heme
oxygenase-1,6,34 and vascular endothelial growth factor,35
protects the ischemic retina. In the present study, we confirmed that a robust, widespread increase in the expression
of the peptide ADM, a HIF-1 target gene and member of
the calcitonin gene-related peptide family, persists over protracted periods of time following SDP and RDP, temporally
coincident with the pattern of HIF-1 expression that was
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triggered by each preconditioning stimulus. Many of the
ADMs cytoprotective and hemodynamic effects in the
CNS36,37 are consistent with a role for this peptide as a key
mediator of ischemic tolerance in the brain and retina. For
example, the ADM upregulates nitric oxide production by
endothelial cells, resulting in vasodilation in many tissues,
including the retina.38,39 Proangiogenic effects of the ADM
are realized secondary to its ability to stimulate, in an autocrine and paracrine manner, endothelial proliferation, and
migration and survival, via receptors located on endothelial
and vascular smooth muscle cells linked to changes in intracellular calcium mobilization, and activation of cAMP and
the opening of potassium channels; its effects on cell migration and survival in retinal pigment epithelial cells, however,
remains controversial.40,41 Cell protection has been documented in neuronal, astrocytic, and vascular CNS models of
in vitro ischemia,42,43 as well as in in vivo stroke models.44,45
Although not causally demonstrated, to date, the fact that
hypoxia,46,47 DFX (present study), cytokines, lipopolysaccharide, and other preconditioning stimuli increases ADM
mRNA and/or ADM protein in the CNS is consistent with
the hypothesis that ADM is an effector molecule in ischemic
tolerance.
Other effector molecules involved in promoting the two
distinct temporal windows of retinal ischemic tolerance following our respective DFX-based preconditioning protocols
remain to be clarified. We emphasize that this protection is
different from that afforded by postischemic treatment of the
retina with DFX and related DFX conjugates, as demonstrated previously by others,48–50 and propose that the respective mechanisms underlying the protection in the preconditioning and postischemic treatment models are, in fact,
largely distinct. We also provided evidence herein that, at
least based on careful morphologic assessments, the single
and repetitive DFX dosing regimens we used to trigger ischemic tolerance did not cause retinal injury in the absence of
ischemia. Although brief ischemia or hypoxia, when titrated
appropriately, also can precondition without apparent harm
to the retina,1,2,6 DFX is an attractive preconditioning agent
with respect to considering the translational aspects of preconditioning because of its longstanding history of use in humans with various hemoglobinopathies and other pathologic
iron disorders, as well as in patients with transfusion-dependent anemias.51 On the other hand, the dose we used for
preconditioning in the present study was about 10 times that
used clinically in such populations; so, given the concerns
about DFX toxicity in patients treated chronically with
DFX,52 and more specifically the retina-related side effects,53
it will ultimately be necessary to determine dose-response
profiles for DFX’s preconditioning effects in different experimental models and to more extensively monitor potentially
injurious ocular outcomes resulting from such treatment.
The obvious aim of these studies would be to eventually
identify acute DFX-dosing regimens that can effectively precondition the human retina without the side effects associated with chronic DFX-treatment paradigms.
Conclusions
Single or multiple doses of DFX can serve as preconditioning stimuli to promote short- or long-lasting periods of
ischemic tolerance in retina. In this study, we provided evi-
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dence consistent with the notion that DFX stabilizes the transcription factor HIF-1 in a dose-dependent manner, and
thereby drives temporally unique expression profiles for cytoprotective molecules, such as ADM, to promote this protective response. The capacity to pharmacologically induce
endogenous adaptive mechanisms and promote a sustained
change in retinal phenotype with clinically well-tolerated
agents, such as DFX, should underscore its potential therapeutic utility in preventing or reducing injury in glaucoma
and other ischemic retinopathies.
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